fashion -WSS

fashion

author：comprehensive 2025-09-07 17:16:53 - browse：47

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market.

The treatment, Lumakras, is designed to treat lung cancer caused by a specific genetic mutation to a protein called KRAS. It’s one of the most common genetic mutations in cancer, but repeated clinical trial failures had led researchers to deem it “undruggable” until a glimmer of hope came about a decade ago.

Lumakras received an accelerated, or conditional, approval in May 2021, making it the first KRAS drug on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Texas board proposes rules on abortion law emergency exemption

hotspot

WSS

FogPharma raises $145 million in rare Series E round

Change Healthcare cyberattack outage could last weeks

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Pregnancy ages women, but effects reverse after delivery

Yancopoulos of Regeneron works to expand Dupixent success

Wikipedia

fashion

focus

Apple is now the first public company to be valued at $3 trillion

FogPharma raises $145 million in rare Series E round

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

FDA does about

Trump demands the U.S. pay no more for drugs than other countries … again

Readout LOUD Podcast: Legal insider trading, booming biotech stocks

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Bring on the sabbaticals for nurses

Sports medicine is finally prioritizing gender equality

ALS groups 'won't be played again' by the FDA, drug sponsors

leisure time

RaDonda Vaught to speak at CommonSpirit event on patient safety

RaDonda Vaught to speak at CommonSpirit event on patient safety

Biotech investment managers search for lucrative opportunities

Biotech investment managers search for lucrative opportunities

Surgeons perform first xenotransplant using CRISPR'd pig kidney

'Patient friction coefficient' can gauge a clinical trial's patient burden

focus

leisure time

hotspot

focus